4basebio PLC (88Q.DE)

EUR 14.6

(0.0%)

EBITDA Summary of 4basebio PLC

  • 4basebio PLC's latest annual EBITDA in 2023 was -7.34 Million GBP , down -35.76% from previous year.
  • 4basebio PLC's latest quarterly EBITDA in 2024 Q2 was -6.23 Million EUR , down 0.0% from previous quarter.
  • 4basebio PLC reported an annual EBITDA of -5.4 Million GBP in 2022, down -68.66% from previous year.
  • 4basebio PLC reported an annual EBITDA of -3.2 Million GBP in 2021, down -829.57% from previous year.
  • 4basebio PLC reported a quarterly EBITDA of -3.91 Million EUR for 2023 Q4, down -13.77% from previous quarter.
  • 4basebio PLC reported a quarterly EBITDA of N/A for 2023 FY, down -35.76% from previous quarter.

Annual EBITDA Chart of 4basebio PLC (2023 - 2019)

Historical Annual EBITDA of 4basebio PLC (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -7.34 Million GBP -35.76%
2022 -5.4 Million GBP -68.66%
2021 -3.2 Million GBP -829.57%
2020 -345 Thousand GBP -104.14%
2019 -169 Thousand GBP 0.0%

Peer EBITDA Comparison of 4basebio PLC

Name EBITDA EBITDA Difference
BioNTech SE 1.08 Billion EUR 100.675%
CureVac N.V. -234.09 Million EUR 96.863%
Biotest Aktiengesellschaft 179 Million EUR 104.102%
Biotest Aktiengesellschaft 179 Million EUR 104.102%
BRAIN Biotech AG -2.38 Million EUR -207.625%
Formycon AG 81.05 Million EUR 109.06%
Heidelberg Pharma AG -18.7 Million EUR 60.746%
Medigene AG -14.58 Million EUR 49.654%